2. Others
  3. Others
  4. P7C3

P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease.

For research use only. We do not sell to patients.

P7C3 Chemical Structure

P7C3 Chemical Structure

CAS No. : 301353-96-8

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 61 In-stock
Solution
10 mM * 1 mL in DMSO USD 61 In-stock
Solid
5 mg USD 55 In-stock
10 mg USD 88 In-stock
50 mg USD 290 In-stock
100 mg USD 480 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of P7C3:

P7C3 Related Antibodies

Top Publications Citing Use of Products

    P7C3 purchased from MedChemExpress. Usage Cited in: Int J Clin Exp Pathol. 2018 Jan 1;11(1):293-303.  [Abstract]

    Expression of Nampt, RelB, Bax, PARP-1 is detected by western blot and hippocampal primary neuronal apoptosis by Flow cytometry. Nampt and RelB protein are up-regulated, and Bax, PARP-1 proteins are down-regulated by P7C3 stimulation in advance compared with Sev-N2O group.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    P7C3 is an orally bioavailable and blood-brain barrier penetrant aminopropyl carbazole, with neuroprotective effects. P7C3 can be used for the research of neurodegenerative diseases, including Parkinson's disease[1][2][3].

    In Vitro

    P7C3 inhibits LPS-induced production of pro-inflammatory factors in BV2 cells[3].
    ? P7C3 markedly reduces the protein levels of iNOS and COX-2 in a dose-dependent manner without affecting the cell viability in the LPS (100 ng/mL)-stimulated BV2 cells[3].
    ? P7C3 inhibits LPS-induced nuclear translocation of NF-κB p65 subunit in BV2 cells[3].
    ? P7C3 suppresses LPS-induced degradation of inhibitory κB alpha (IκBα) by inhibiting IκB kinase (IKK) activation[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    P7C3 Related Antibodies

    Western Blot Analysis[3]

    Cell Line: BV2 cells
    Concentration: 0.1 μM, 1 μM, 10 μM
    Incubation Time: 2 hours
    Result: Reduced the protein levels of iNOS, COX-2.
    In Vivo

    P7C3 (20 mg/kg/d; i.p.; twice daily; for 21 days ) inhibits microglial activation and microglia-mediated dopaminergic (DA) neuronal loss in vivo[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: 6-8 weeks male C57BL/6 mice (25-30 g)[3]
    Dosage: 20 mg/kg/d
    Administration: Intraperitoneal injection, twice daily, for 21 days
    Result: Strikingly decreased the expressions of (a microglia marker) and GFAP (an astrocyte marker) LPS-induced in the substantia nigra pars compacta (SNpc).
    Molecular Weight

    474.19

    Formula

    C21H18Br2N2O
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    OC(CNC1=CC=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 33 mg/mL (69.59 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.1089 mL 10.5443 mL 21.0886 mL
    5 mM 0.4218 mL 2.1089 mL 4.2177 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.08 mg/mL (4.39 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.85%

    SDS (581 KB)

    COA (249 KB) HNMR (281 KB) LCMS (267 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1089 mL 10.5443 mL 21.0886 mL 52.7215 mL
    5 mM 0.4218 mL 2.1089 mL 4.2177 mL 10.5443 mL
    10 mM 0.2109 mL 1.0544 mL 2.1089 mL 5.2721 mL
    15 mM 0.1406 mL 0.7030 mL 1.4059 mL 3.5148 mL
    20 mM 0.1054 mL 0.5272 mL 1.0544 mL 2.6361 mL
    25 mM 0.0844 mL 0.4218 mL 0.8435 mL 2.1089 mL
    30 mM 0.0703 mL 0.3515 mL 0.7030 mL 1.7574 mL
    40 mM 0.0527 mL 0.2636 mL 0.5272 mL 1.3180 mL
    50 mM 0.0422 mL 0.2109 mL 0.4218 mL 1.0544 mL
    60 mM 0.0351 mL 0.1757 mL 0.3515 mL 0.8787 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    P7C3 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    P7C3301353-96-8Othersneuroprotectiveneurodegenerationneurodegenerative diseasesnervecellinjuryParkinson'sdiseaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    P7C3
    Cat. No.:
    HY-15976
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (581 KB) Français - FR (581 KB) Deutsch - DE (581 KB) Norwegian - NO (581 KB) Español - ES (581 KB) Swedish - SV (581 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.